effect of amiloride-h in central serous chorioretinopathy

Phase 3

Recruiting

• Conditions: Central serous chorioretinopathy.; Central serous chorioretinopathy, unspecified eye; H35.719

• Registration Number: IRCT20190311043009N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 21 May 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Presence of acute central serous chorioretinopathy less than past month

Exclusion Criteria

presence of ophthalmologic pathology same as glaucoma, retinal disease and uveitis
use of previuos treatment, like as medical, PDT, laser photocoagulation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Best corrected visual acuity based on snellen chart. Timepoint: Measurement of best corrected visual acuity of the patient at first and 1, 3 month after begining treatment. Method of measurement: Snellen chart board.

Secondary Outcome Measures

Name	Time	Method
Central macular thickness. Timepoint: At first and 1, 3 months after treatment. Method of measurement: Imaging of the retina with use of optical coherence tomography.